Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Business Development | April 30, 2021 | May 04, 2021 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 30, 2021 · Filed May 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,146 |
Reported balance
After 2021-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-30 · Grant · Acquired 709 · Balance 45,146 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. |
| Common StockSEC Table I · non-derivative | Direct | 45,007 |
Reported balance
After 2021-05-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-05-01 · Tax withholding · Disposed 139 · Balance 45,007 |
| Common StockSEC Table I · non-derivative | Direct | 44,787 |
Reported balance
After 2021-05-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-05-03 · Tax withholding · Disposed 220 · Balance 44,787 F2: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $239.64 · Expires 2031-04-30 | Direct | 6,159 |
Reported balance
After 2021-04-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-30 · Grant · Acquired 6,159 · Balance 6,159 F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.
F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 20:22 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001610717-26-000171 · form4.xml · derivative · entry 1 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-05-26 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-079921 · ownership.xml · derivative · entry 5 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-05-27 F5 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079921 · ownership.xml · derivative · entry 4 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079921 · ownership.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079921 · ownership.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079921 · ownership.xml · derivative · entry 1 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022321 · ownership.xml · derivative · entry 4 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022321 · ownership.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $9.95 | Not disclosed |
DisclosureSEC source: 0000950170-25-022321 · ownership.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-022321 · ownership.xml · derivative · entry 1 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:16 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001610717-24-000337 · form4.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:16 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000337 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:56 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000285 · form4.xml · derivative · entry 1 Piacquad David · CIK 0001602343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-13 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 23:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 220 | $239.64 | $52,720.80 |
DisclosureSEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,787 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 01, 2021 Filed May 4, 2021 23:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 139 | $239.64 | $33,309.96 |
DisclosureSEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,007 Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 6,159 | $0.00 Strike: $239.64 | $0.00 |
DisclosureSEC source: 0001127602-21-015364 · form4.xml · derivative · entry 4 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,159 Underlying: Common Stock · 6,159 shares Expires 2031-04-30 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,146 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 00:14 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 128 | $255.52 | $32,706.56 |
DisclosureSEC source: 0001127602-21-014605 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,437 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which will vest on 5/1/2021; 326 RSUs which will vest on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 206 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 22:33 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 991 | $244.42 | $242,220.22 |
DisclosureSEC source: 0001127602-21-011714 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,565 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 234 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 01:33 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009482 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,504 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 202 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 10,628 | $0.00 Strike: $236.36 | $0.00 |
DisclosureSEC source: 0001127602-20-015864 · form4.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,628 Underlying: Common Stock · 10,628 shares Expires 2030-05-05 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015864 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,773 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 03, 2020 Filed May 5, 2020 23:55 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 136 | $230.98 | $31,413.28 |
DisclosureSEC source: 0001127602-20-015551 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,504 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:55 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 123 | $239.22 | $29,424.06 |
DisclosureSEC source: 0001127602-20-015551 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,640 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:02 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 116 | $236.28 | $27,408.48 |
DisclosureSEC source: 0001127602-20-014701 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,763 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 188 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:03 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,591 | $198.76 | $316,227.16 |
DisclosureSEC source: 0001127602-20-011869 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,879 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 206 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:52 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009711 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,411 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 176 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 01:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 9,264 | $229.93 | $2,130,078.93 |
DisclosureSEC source: 0001127602-20-004438 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,700 F1 · price: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 176 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| December 13, 2019 Filed Dec 14, 2019 01:31 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-19-034963 · form4.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,839 Underlying: Common Stock · 2,875 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 14, 2019 01:31 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,425 | $235.99 | $572,275.75 |
DisclosureSEC source: 0001127602-19-034963 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,964 F1 · balance_after: Non-market exercise of 2,875 stock options expiring May 1, 2027 wherein 2,425 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 176 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| December 13, 2019 Filed Dec 14, 2019 01:31 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 2,875 | $162.60 | $467,475.00 |
DisclosureSEC source: 0001127602-19-034963 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 01:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,749 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-19-033442 · form4.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,962 Underlying: Common Stock · 5,749 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 01:09 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,870 | $224.50 | $1,093,315.00 |
DisclosureSEC source: 0001127602-19-033442 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,491 F1 · balance_after: Non-market exercise of 5,749 stock options expiring May 3, 2026 wherein 4,870 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest in one installment on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 153 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 01:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,749 | $156.35 | $898,856.15 |
DisclosureSEC source: 0001127602-19-033442 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 14,768 | $0.00 Strike: $177.31 | $0.00 |
DisclosureSEC source: 0001127602-19-017652 · form4.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,768 Underlying: Common Stock · 14,768 shares Expires 2029-05-03 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017652 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,555 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:04 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 182 | $176.50 | $32,123.00 |
DisclosureSEC source: 0001127602-19-017652 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,864 Read SEC document |
| May 01, 2019 Filed May 3, 2019 22:02 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 171 | $179.32 | $30,664.27 |
DisclosureSEC source: 0001127602-19-017355 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,046 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 124 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 23:39 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,509 | $191.89 | $289,562.01 |
DisclosureSEC source: 0001127602-19-013164 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,217 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 142 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 06, 2019 Filed Mar 9, 2019 00:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010658 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,674 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 120 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 162 | $192.11 | $31,121.82 |
DisclosureSEC source: 0001127602-19-003512 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,998 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 120 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $54.69 | $0.00 |
DisclosureSEC source: 0001127602-18-035030 · form4.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires 2021-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,109 | $202.37 | $831,538.33 |
DisclosureSEC source: 0001127602-18-035030 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,019 F1 · balance_after: Non-market exercise of 6,500 stock options expiring April 25, 2021 wherein 4,109 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 136 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 6,500 | $54.69 | $355,485.00 |
DisclosureSEC source: 0001127602-18-035030 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 15, 2018 23:55 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $54.71 | $0.00 |
DisclosureSEC source: 0001127602-18-017562 · form4.xml · derivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 15, 2018 23:55 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 9,860 | $170.77 | $1,683,792.20 |
DisclosureSEC source: 0001127602-18-017562 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,706 F1 · balance_after: Non-market exercise of 15,000 stock options expiring August 3, 2020 wherein 9,860 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 94 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 11, 2018 Filed May 15, 2018 23:55 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 15,000 | $54.71 | $820,650.00 |
DisclosureSEC source: 0001127602-18-017562 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 23:11 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 178 | $169.43 | $30,158.54 |
DisclosureSEC source: 0001127602-18-016539 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,566 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 94 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 7,374 | $0.00 Strike: $177.46 | $0.00 |
DisclosureSEC source: 0001127602-18-015843 · form4.xml · derivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,374 Underlying: Common Stock · 7,374 shares Expires 2028-04-27 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015843 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,744 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.